Literature DB >> 33876296

Crohn's disease: a population-based study of surgery in the age of biological therapy.

Christian Stöss1, Maximilian Berlet1, Stefan Reischl1, Ulrich Nitsche1, Marie-Christin Weber1, Helmut Friess1, Dirk Wilhelm1, Philipp-Alexander Neumann2.   

Abstract

PURPOSE: Despite primary conservative therapy for Crohn's disease, a considerable proportion of patients ultimately needs to undergo surgery. Presumably, due to the increased use of biologics, the number of surgeries might have decreased. This study aimed to delineate current case numbers and trends in surgery in the era of biological therapy for Crohn's disease.
METHODS: Nationwide standardized hospital discharge data (diagnosis-related groups statistics) from 2010 to 2017 were used. All patients who were admitted as inpatient Crohn's disease cases in Germany were included. Time-related development of admission numbers, rate of surgery, morbidity, and mortality of inpatient Crohn's disease cases were analyzed.
RESULTS: A total number of 201,165 Crohn's disease cases were included. Within the analyzed time period, the total number of hospital admissions increased by 10.6% (n = 23,301 vs. 26,069). While gender and age distribution remained comparable, patients with comorbidities such as stenosis formation (2010: 10.1%, 2017: 13.4%) or malnutrition (2010: 0.8%, 2017: 3.2%) were increasingly admitted. The total number of all analyzed operations for Crohn's disease increased by 7.5% (2010: n = 1567; 2017: n = 1694). On average, 6.8 ± 0.2% of all inpatient patients received ileocolonic resections. Procedures have increasingly been performed minimally invasive (2010: n = 353; 2017: n = 687). The number of postoperative complications remained low.
CONCLUSION: Despite the development of novel immunotherapeutics, the number of patients requiring surgery for Crohn's disease remains stable. Interestingly, patients have been increasingly hospitalized with stenosis and malnutrition. The trend towards more minimally invasive operations has not relevantly changed the rate of overall complications.

Entities:  

Keywords:  Crohn’s disease; IBD; Immunotherapeutics; Surgery

Year:  2021        PMID: 33876296     DOI: 10.1007/s00384-021-03930-w

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  19 in total

Review 1.  Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.

Authors:  Alexandra D Frolkis; Jonathan Dykeman; María E Negrón; Jennifer Debruyn; Nathalie Jette; Kirsten M Fiest; Talia Frolkis; Herman W Barkema; Kevin P Rioux; Remo Panaccione; Subrata Ghosh; Samuel Wiebe; Gilaad G Kaplan
Journal:  Gastroenterology       Date:  2013-07-27       Impact factor: 22.682

2.  [Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations].

Authors:  E Swart; H Gothe; S Geyer; J Jaunzeme; B Maier; T G Grobe; P Ihle
Journal:  Gesundheitswesen       Date:  2015-01-26

3.  Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Tim R A van den Heuvel; Limmie Y L Liu; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2016-12-06       Impact factor: 10.864

4.  Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis.

Authors:  Antonino Spinelli; Piero Bazzi; Matteo Sacchi; Silvio Danese; Gionata Fiorino; Alberto Malesci; Lorenzo Gentilini; Gilberto Poggioli; Marco Montorsi
Journal:  J Gastrointest Surg       Date:  2012-09-05       Impact factor: 3.452

Review 5.  Complications and surgery in the inflammatory bowel diseases biological era.

Authors:  Harry Sokol; Philippe Seksik; Jacques Cosnes
Journal:  Curr Opin Gastroenterol       Date:  2014-07       Impact factor: 3.287

Review 6.  Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.

Authors:  Benjamin Misselwitz; Pascal Juillerat; Michael Christian Sulz; Britta Siegmund; Stephan Brand
Journal:  Digestion       Date:  2020-06-22       Impact factor: 3.216

Review 7.  Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.

Authors:  E J Mao; G S Hazlewood; G G Kaplan; L Peyrin-Biroulet; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2016-11-10       Impact factor: 8.171

Review 8.  TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update.

Authors:  Marianne Vulliemoz; Stephan Brand; Pascal Juillerat; Christian Mottet; Shomron Ben-Horin; Pierre Michetti
Journal:  Digestion       Date:  2020-07-31       Impact factor: 3.216

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 10.  Fibrostenotic strictures in Crohn's disease.

Authors:  Jun Hwan Yoo; Stefan Holubar; Florian Rieder
Journal:  Intest Res       Date:  2020-04-10
View more
  1 in total

1.  Assessment of influencing factors of hospitalization expenses for Crohn's disease patients: Based on LASSO and linear mixed model.

Authors:  Li Wu; Zhijie Lv; Linjing Lai; Penglei Zhou
Journal:  Front Public Health       Date:  2022-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.